HEMOGENYX PHARMACEUTICALS PLC

Remuneration Information • Apr 11, 2018

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 6393K

Hemogenyx Pharmaceuticals PLC

11 April 2018

Hemogenyx Pharmaceuticals Plc 

("Hemogenyx" or the "Company")

Director / PDMR Shareholding

Hemogenyx Pharmaceuticals Plc (LSE: HEMO), the biotechnology company developing novel therapies to transform bone marrow, or blood stem cell, transplantation for the treatment of blood diseases, announces that on 9 April 2018 options to subscribe for 18,002,568 ordinary shares of £0.01 each in the Company  ("Ordinary Shares" and the "Options") were granted to Professor Sir Marc Feldmann, Chairman, Hemogenyx.

The Options were granted as part of a remuneration package. The exercise price  of the an Option is £0.035 per Option Share. The Option Shares shall vest in 12 quarterly instalments in arrears on and with effect from the first Vesting Date, being 30 June 2018.

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Marc Feldmann 

2

Reason for the notification

a)

Position/status

Chairman

b)

Initial notification /Amendment

Amendment to prior notifications

00038962

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hemogenyx Pharmaceuticals PLC

b)

LEI

2138008L93GYU5GN6179

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Identification code

Grant of Option

b)

Nature of the transaction

Acceptance of a stock option granted as part of a remuneration package

c)

Price(s) and volume(s)

Price	Volume
0.035	18002568

d)

Date of the transaction

9 April 2018

e)

Place of the transaction

Outside of a trading venue

Enquiries:

Hemogenyx Pharmaceuticals Limited		www.hemogenyx.com
Dr Vladislav Sandler, Chief Executive Officer & Co-Founder		Via Walbrook PR
Sir Marc Feldmann, Chairman
Optiva Securities Ltd		Tel: +44 (0)20 3137 1902
Christian Dennis
Shard Capital Partners LLP		Tel: +44 (0)20 7186 9950
Damon Heath, Erik Woolgar
Peterhouse Corporate Finance Limited		Tel: +44 (0)20 7469 0930
Lucy Williams/Duncan Vasey
Walbrook PR (UK Media & Investor Relations)	Tel: +44 (0)20 7933 8780 or hemogenyx@walbrookpr.com
Paul McManus	Mob: +44 (0)7980 541 893
US Media enquiries
Lowell Goodman	Tel: +1 (323) 646-3249 or lowell@lowellgoodman.net

About Hemogenyx Pharmaceuticals Plc

Hemogenyx Pharmaceuticals Plc is a publicly traded company (LSE: HEMO) headquartered in London, with its wholly owned U.S. operating subsidiary, HemoGenyx LLC, located in its state-of-the-art research facility in Brooklyn, New York.

HemoGenyx is a preclinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies and treatments for blood diseases such as leukemia and lymphoma. The company's leading technologies aim to change the way in which bone marrow/hematopoietic stem cell (BM/HSC) transplants are performed and improve their efficacy. HemoGenyx's two distinct and complementary products include an immunotherapy product for patient conditioning-the CDX bi-specific antibody-and a cell therapy product for BM/HSC transplantation-the HuPHEC. Each of these products holds the potential to revolutionize the way BM/HSC transplants are being performed, offering solutions that mitigate the dangers and limitations associated with the current standard of care.

For more information, visit www.hemogenyx.com.

This information is provided by RNS

The company news service from the London Stock Exchange

END

DSHBLGDSUBBBGIB